Pharmaceutical Name
Parvovirus Vaccine, Modified Live Virus

• High antigenic mass (titer), low passage parvovirus vaccine.

• Contains parvovirus type 2b, the most prevalent field strain of parvovirus.

• Canine parvovirus type 2b protects against all field strains currently seen.

• Overrides maternal antibodies in young puppies. Primary vaccination may begin as early as 6 weeks. Last dose may be given at 12 weeks of age. 

Indications
For the vaccination of healthy dogs against canine parvovirus.

Dosage
For further information including dose rate and complete directions and warnings, please see the Product Label by clicking here.
 
Galaxy^® Pv is a registered trademark of Schering-Plough Animal Health Corporation.